April 11, 2022

Xigduo® XR (dapagliflozin/metformin) has received a new indication for one of its active pharmaceutical ingredients (APIs), dapagliflozin, to reduce the risk of sustained estimated glomerular filtration rate (EGFR) decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults who have chronic kidney disease at risk of progression.

  • Xigduo XR’s other API, metformin, is indicated as an adjunct to diet and exercise to improve glycemic control in adults who have type 2 diabetes mellitus. Dapagliflozin holds two additional indications to reduce the risk of:
    • Hospitalization for heart failure in adults who have type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors.
    • Cardiovascular death and hospitalization for heart failure in adults who have heart failure (NYHA class II-IV) with reduced ejection fraction.
  • Due to the metformin component, Xigduo XR should only be used in the treatment of adults who have type 2 diabetes. The FDA first approved Xigduo XR in 2014.
  • Recommended dosing is based on a variety of factors, such as the patient’s current treatment regimen and treatment effectiveness and tolerability. Xigduo XR is taken by mouth once daily in the morning with food.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More